Orforglipron cuts predicted 10-year diabetes risk in ATTAIN-1 post hoc analysis

The wire

1. 01Post hoc analysis of ATTAIN-1 found orforglipron 5.5, 9 and 17.2 mg cut predicted 10-year type 2 diabetes risk 48.6% to 59.4% versus 10.5% with placebo at 72 weeks.
2. 02Once-daily oral orforglipron is Lilly's non-peptide GLP-1 candidate; modelled cardiometabolic benefit is the kind of data prescribers will weigh against injectable incretins.
3. 03Results come from validated risk engines, not observed events, in adults with overweight or obesity without diabetes; actual outcome trials remain outstanding.

From the source

Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial

Diabetes, obesity & metabolism · 2026 Sep 17 · Shinde S, Kahles F, Vasileva-Metodiev S et al.